MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded by a short open reading frame (sORF) within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). It was discovered in 2015 by Changhan Lee and colleagues in the Pinchas Cohen laboratory at the USC Leonard Davis School of Gerontology. MOTS-c is the first mitochondria-derived peptide demonstrated to regulate nuclear gene expression and systemic metabolism.
MOTS-c belongs to a class of signaling molecules called mitochondrial-derived peptides (MDPs) or "mitokines," which are hormone-like signals released by mitochondria to communicate their energy status to the rest of the cell and body. Other MDPs include humanin and SHLP1-6, each with distinct metabolic and cytoprotective functions. The discovery that the mitochondrial genome harbors bioactive peptide-coding sequences transformed understanding of mitochondrial biology beyond ATP production.
The "exercise mimetic" designation derives from preclinical research showing that MOTS-c administration reproduces several key metabolic adaptations to aerobic exercise training, including improved insulin sensitivity, enhanced mitochondrial respiratory capacity, increased exercise endurance, and improved body composition, even in aged animals. In humans, exercise induces endogenous MOTS-c expression in skeletal muscle (up to 12-fold increase) and in circulation (~50% increase), and circulating MOTS-c levels decline significantly with aging.
Critical evidence context: While MOTS-c's preclinical data is genuinely compelling, calling it "exercise in a bottle" (as biohacking communities do) overstates the evidence. "Mimics some biochemical signaling features of exercise" is accurate; "replaces exercise" is not. No large randomized controlled therapeutic trials have been completed in humans. MOTS-c is WADA-prohibited as of 2024.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–2 | 0.2 mg | 6 units0.06 mL |
| Weeks 3–4 | 0.4 mg | 12 units0.12 mL |
| Weeks 5–6 | 0.6 mg | 18 units0.18 mL |
| Weeks 7–8 | 0.8 mg | 24 units0.24 mL |
| Weeks 9–10+ | 1 mg | 30 units0.3 mL |
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–2 | 0.2 mg | 1.5 units0.01 mL |
| Weeks 3–4 | 0.4 mg | 3 units0.03 mL |
| Weeks 5–6 | 0.6 mg | 4.5 units0.04 mL |
| Weeks 7–8 | 0.8 mg | 6 units0.06 mL |
| Weeks 9–10+ | 1 mg | 7.5 units0.07 mL |
FrequencyOnce daily, subcutaneous, in the morning.
For review — no human dosing exists. MOTS-c has only rodent data, spanning 0.5 to 50 mg/kg; the schedule in the chart comes from a circulated protocol rather than from that literature. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no human study establishes any frequency for MOTS-c.
MOTS-c has no human dosing at all: the published range is 0.5 to 50 mg/kg in mice, a hundredfold spread that is itself the finding, since the animal literature has not converged on an amount. The week-by-week amounts charted here are a circulated protocol rather than a figure from that literature, and they are flagged for review rather than presented as dosing. A 10 mg vial made up with 3 mL is about 3.33 mg/mL and a 40 mg vial with 3 mL is about 13.3 mg/mL, so the 1 mg top step is 30 units from the smaller vial and 7.5 units from the larger, and every row on both charts stays inside one 50-unit syringe. The opening 0.2 mg step is only a 1.5-unit draw from the 40 mg vial, small enough that the 10 mg vial measures the early weeks more reliably. MOTS-c is a mitochondrial-derived peptide whose effects in mice depend heavily on metabolic state, which is a further reason its rodent figures do not scale into a human schedule.
What this evidence establishes. MOTS-c has no human dosing. The range below is from rodent studies and spans a hundredfold, with protocols that vary as much as the doses do — which is itself the finding: the animal literature has not converged on a dose. Milligram-per-kilogram figures from mice do not scale directly to humans, and no conversion of them is offered here.
Sources: Animal literature range reported on this site's MOTS-c profile
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
MOTS-c's primary mechanism involves AMPK activation through an unconventional pathway, plus direct nuclear translocation for gene expression regulation:
Inhibits the folate cycle and de novo purine synthesis, causing AICAR (an endogenous AMPK activator) to accumulate. Activates AMPK independently of cellular energy depletion.
Translocates from mitochondria to the nucleus during metabolic stress, directly regulating nuclear gene expression. First MDP shown to do this.
Reproduces metabolic adaptations to aerobic training: improved insulin sensitivity, enhanced mitochondrial respiration, increased exercise capacity, and fat oxidation.
Stimulates glucose uptake and utilization in skeletal muscle. Improves glucose tolerance and reduces insulin resistance in diet-induced obesity models.
Promotes mitochondrial content and function through AMPK-dependent pathways. Restores mitochondrial respiration in metabolically impaired tissue.
Circulating MOTS-c levels decline significantly with chronological aging (up to 21% lower in older adults), correlating with metabolic dysfunction associated with aging.
MOTS-c has no established human safety profile from therapeutic clinical trials. The following assessments are derived from preclinical models and limited human observational data:
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| WADA-tested athletes | PROHIBITED | MOTS-c is explicitly banned by WADA as of 2024. Use constitutes a doping violation. |
| Active malignancy | HIGH (theoretical) | AMPK activation has context-dependent effects on cancer biology. In some cancers AMPK is tumor-suppressive; in others, metabolic enhancement could support tumor growth. Unstudied in this context. |
| Pregnancy / breastfeeding | UNKNOWN | No reproductive toxicology data. Standard precaution for unstudied compounds. |
| Diabetes medications (metformin, insulin) | MODERATE (theoretical) | MOTS-c activates AMPK, the same target as metformin. Additive hypoglycemic effects possible. No drug interaction studies conducted. |
| Ethnic-specific mtDNA variations | LOW (research context) | MOTS-c effects in humans appear affected by race via ethnic-specific mtDNA variations. Response variability is expected but clinical significance is unclear. |
| Dose-response variability | MODERATE | Published animal doses range from 0.5 to 50 mg/kg with widely varying protocols. No established human therapeutic dose exists. |
| Folate metabolism interference | MODERATE (theoretical) | MOTS-c inhibits the folate cycle as part of its AMPK activation mechanism. Potential interactions with folate-dependent processes (pregnancy, methotrexate use) are unstudied. |
| Long-term safety | UNKNOWN | Chronic AMPK activation effects in humans are not characterized for MOTS-c. Long-term consequences of exogenous mitokine supplementation are entirely unknown. |
| Animal tolerability | FAVORABLE (preclinical) | Animal models show good tolerability across multiple species and dose ranges. No significant toxicity signals in published preclinical studies. |
| Human therapeutic trial data | ABSENT | No completed large randomized controlled therapeutic trials in humans. Human data is limited to observational studies measuring endogenous MOTS-c levels. |
FDA: MOTS-c is not FDA-approved for any indication. It has not been submitted for IND application. It is classified as an experimental research compound.
WADA: MOTS-c is explicitly prohibited by the World Anti-Doping Agency beginning in 2024, reflecting its demonstrated performance-enhancing potential in preclinical exercise capacity models.
Key distinction: MOTS-c occupies an unusual position in peptide science. It is an endogenous mitochondrial peptide with genuinely compelling preclinical data published in top-tier journals (Nature Communications, Cell Metabolism). It was discovered at a major research university (USC), not in a supplement company lab. The underlying biology, specifically mitochondrial-nuclear communication via MDPs, is real and important. However, "real science" and "ready for therapeutic use" are very different things. The gap between preclinical promise and clinical validation has not been bridged. Exercise remains the proven, safe, and free way to activate the pathways MOTS-c targets.
Test your understanding of MOTS-c's mitochondrial biology, mechanism, and evidence limitations.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.